← Eichor
Study identifier: NCT06261840 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Refining Treatment Options for Trichomonas Vaginalis Infection: A Comparative Analysis of Metronidazole and Secnidazole

Condition: Trichomonas Vaginitis · Bacterial Vaginitis  ·  Sponsor: Tulane University

PhasePhase 4
Planned participants1200
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

This is a multi-centered, randomized, open-label, parallel, phase IV clinical trial comparing the effectiveness and cost-effectiveness of oral multi-dose metronidazole (MTZ) and oral single-dose secnidazole (SEC) for the treatment of Trichomonas vaginalis in both women and men.

This description comes directly from the study's public registry record.

Talk to the study team

Patricia Kissinger, PhD  ·  504-988-7320  ·  kissing@tulune.edu

Christina Muzny, MD  ·  205-975-3298  ·  cmuzny@uabmc.edu

Always discuss trial participation with your own doctor first.

Locations (4)

University of Alabama at Birmingham [UAB] Gynecology ClinicsBirmingham, Alabama, United StatesRecruiting
UAB Sexual Health Research Clinic [SHRC]Birmingham, Alabama, United StatesRecruiting
Segal Trials Healthcare Clinical Data, Inc. 1065 NE 125th St. Suite 417 North Miami, FL 33161North Miami, Florida, United StatesNot Yet Recruiting
LSU-CrescentCare Sexual Health CenterNew Orleans, Louisiana, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06261840